Bristol-Myers Squibb Company BMY
58.80 USD +0.46 (+0.79%)
Regular-session close
59.00 +0.20 +0.34%
After hours · Nov 20, 7:36 PM ET
58.70 Day range 59.81
45.94 52-week range 68.09
- YTD
- +9.01%
- 1 year
- +27.99%
News
fool.com Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy for 2027? Bristol Myers Squibb maintains a powerful portfolio in oncology and hematology while trading at a low valuation multiple. Novo Nordisk dominates the rapidly expanding markets for obesity and diabetes…
fool.com Bristol Myers Squibb's Growth Portfolio Just Hit $7.7 Billion. Is This Cheap Pharma Stock a No-Brainer Buy? Bristol Myers Squibb has an attractive 4.3% yield, and its P/E is below average for a drug maker. The pharma giant has a long history of successfully developing and marketing new drugs.
247wallst.com 4 Dividend Stocks Wall Street Gave Up On With Balance Sheets Built to Recover When a stock falls out of favor, the balance sheet decides what happens to your income. A company with manageable debt and steady cash flow can keep paying shareholders while it repairs the business.
247wallst.com 3 Big Pharma Dividend Stocks Built for Retirement Income Three drugmakers promise retirees steady paychecks, yet one faces a looming Eliquis cliff and two pay in foreign currencies that can shrink the check. Which dividend is safest when earnings look…
247wallst.com Vanguard’s Little-Known Value ETF Skips the Index and Goes Straight for the Cheapest Stocks Vanguard quietly runs an actively managed value fund that hunts for bargains across every company size, and it just beat its famous index sibling over the past year. Before you switch, check what it…
businesswire.com Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026 PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH--Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026.benzinga.com Evotec, Bristol Myers Squibb Protein Degradation Partnership Receives Second FDA Investigational New Drug Acceptance For CELMoD Candidate, Phase 1 Expected In 2027 FDA clearance expands partnered molecular glue pipelineAchievement underscores productivity of the collaboration in molecular glue discovery and potential to address patient populations with high…
zacks.com Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy? MRK emerges as the stronger investment choice over BMY, backed by superior stock performance, oncology leadership, pipeline expansion and diversified growth drivers.
fool.com Bristol-Myers Squibb: 3 Key Takeaways for Long-Term Investors Growth portfolio revenue rose 12% year over year to $7.7 billion. Eight growth portfolio medicines annualized over $1 billion each.
benzinga.com Bristol Myers Squibb Says KarXT Reduces Hallucinations and Delusions In Preliminary Alzheimer's Trials Bristol Myers Squibb & Co. (NYSE:BMY) on Wednesday released preliminary Phase 3 data showing that short- and long-term KarXT treatment reduced symptoms in patients experiencing psychosis associated…
benzinga.com Bristol Myers Squibb Says KarXT Reduces Hallucinations and Delusions In Preliminary Alzheimer's Trials Bristol Myers Squibb reports Phase 3 ADEPT data showing KarXT reduces hallucinations, delusions, and severity in Alzheimer's psychosis.
zacks.com Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline? MRK ends nemtabrutinib development after phase III safety concerns, shifting focus to its expanding pipeline assets.
reuters.com Bristol's schizophrenia drug helps Alzheimer's-related psychosis symptoms, preliminary data shows Bristol's schizophrenia drug helps Alzheimer's-related psychosis symptoms, preliminary data showsbenzinga.com Bristol Myers Reports Preliminary Phase 3 Findings Of KarXT Treatment From 12-Week Open-Label Period Of ADEPT-1 Study And 52-Week OLE ADEPT-3 Study In Patients With Psychosis Associated With Alzheimer’s Disease Preliminary findings from the ADEPT-1 12-week open-label lead-in period show observed improvements in hallucination and delusion scores from baselinePreliminary findings from the ADEPT-3 52-week…
businesswire.com Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer's Disease PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ADEPT--BMS Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer's Disease.
zacks.com Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.benzinga.com Reported November 16, Roche Receives FDA Approval For Wiserdley In Combination With Everolimus For Breast Cancer Treatment Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a post-CDK4/6 inhibitor setting in a head-to-head phase III…
benzinga.com Bristol Myers Squibb Appoints Cristian Massacesi To Lead A Unified, End-To-End R&D Organization, Effective January 1, 2027 As part of this planned transition, Robert Plenge will remain with Bristol Myers Squibb in an advisory capacity through March 2027 to support a seamless transition before departing the…
benzinga.com EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat Democrats have two ways to pressure drugmakers. Eli Lilly, Gilead, Merck, Bristol Myers face different levels of Medicare pricing exposure.
benzinga.com Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields Healthcare dividend stocks PRGO (7.32%), BMY (4.06%) and GSK (3.65%) feature analyst ratings and recent company news.benzinga.com Bristol Myers Squibb Presents 56-Week Results From Phase 3 SCOUT-HCM Clinical Trial In Late-Breaker Presentation At HCMS Scientific Sessions With a consistent efficacy and safety profile through 56-weeks of follow-up, the Phase 3 SCOUT-HCM clinical trial further reinforces Camzyos as the first approved treatment for pediatric patients ≥30…
benzinga.com Tempus AI Says It Is Uniquely Positioned Tempus AI stock rises after beating Q3 earnings estimates and securing $192.5 million in data deals with Bristol Myers Squibb and Pathos.benzinga.com Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Lowers Price Target to $40 Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and lowers the price target from $41 to $40.
benzinga.com Bristol-Myers Squibb Says AI Is Already Speeding Up Drug Research — And It's Measuring The Impact Bristol-Myers beats Q3 2026 estimates with $13.07B in revenue and raises full-year sales guidance driven by newer drug growth.
benzinga.com Bristol-Myers Squibb Q3 2026 Earnings Call Transcript Bristol-Myers Squibb (NYSE:BMY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com Bristol-Myers Squibb Lowers FY2026 Adj EPS Guidance from $6.75-$7.00 to $6.35-$6.55 vs $6.54 Est; Raises FY2026 Sales Guidance from $49.000B-$50.000B to $49.750B-$50.250B vs $49.886B Est Bristol-Myers Squibb (NYSE:BMY) lowers FY2026 Adj EPS guidance from $6.75-$7.00 to $6.35-$6.55 vs $6.54 analyst estimate. Raises FY2026 sales outlook from $49.000 billion-$50.000 billion to $49.750…
benzinga.com Bristol-Myers Squibb Q3 Adj. EPS $1.35 Beats $1.17 Estimate, Sales $13.069B Beat $12.738B Estimate Bristol-Myers Squibb (NYSE:BMY) reported quarterly earnings of $1.35 per share which beat the analyst consensus estimate of $1.17 by 15.38 percent. This is a 17.18 percent decrease over earnings of…
benzinga.com Traders Are Pricing a 7% Swing in Amazon Ahead of Earnings Amazon, Intel, Sandisk and six other stocks report earnings Thursday. See implied moves, analyst estimates and the billions in market value at stake.
benzinga.com Amazon, Eli Lilly On Deck Thursday As AWS Growth, Drug Demand Face Test Amazon headlines Thursday’s reports, with investors focused on whether accelerating AWS growth and heavy AI spending can support the next leg of its expansion. Eli Lilly, Mastercard, Merck,…benzinga.com Piper Sandler Maintains Overweight on Bristol-Myers Squibb, Lowers Price Target to $78 Piper Sandler analyst David Amsellem maintains Bristol-Myers Squibb (NYSE:BMY) with a Overweight and lowers the price target from $82 to $78.
benzinga.com Bristol Myers Squibb, SystImmune’s Iza-Bren Hits Primary Endpoint In Phase 3 PANKU-Lung01 Interim Analysis, Median PFS 11.1 Versus 5.7 Months (HR 0.40) Over Platinum Chemotherapy In EGFR-Mutated NSCLC Late-breaking results to be presented in an oral presentation at ESMO 2026PANKU-Lung01 is the first Phase 3 trial to evaluate a dual-targeting EGFRxHER3 bispecific antibody-drug conjugate in this…
benzinga.com What's Going On with Bristol Myers Squibb Stock on Friday? Bristol Myers Squibb releases trial results for their multiple sclerosis CAR T therapy and Phase 3 breast cancer conjugate candidate.benzinga.com Bristol Myers Squibb Presents Interim Safety, Efficacy Data From Its Multiple Sclerosis Groups Of Phase 1 Trial Of Zolacabtagene Autoleucel At MSToronto 2026 Bristol Myers Squibb (NYSE:BMY) today announced disclosure of interim safety and efficacy results from the multiple sclerosis (MS) cohorts of the Phase 1, single-arm, dose-escalation Breakfree-2…
benzinga.com Tempus AI Enters Multiyear Agreement With Bristol Myers Squibb For BMY To License Multimodal Oncology Data Through 2031 To Support Biological And Clinical Insight Identification, Novel Drug Target Discovery And Therapeutic Development Across Its Oncology Portfolio Additionally, BMS will gain access to Tempus’ Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world’s largest, real-world multimodal datasets. Connected…
benzinga.com SystImmune And Bristol Myers Report Phase 3 PANKU-Breast01 Interim Analysis Shows Izalontamab Brengitecan Cuts Progression Or Death Risk By 59% Vs Chemotherapy in HR+/HER2- Metastatic Breast Cancer; Results To Be Presented At ESMO 2026 Late-breaking results to be presented in an oral presentation at ESMO 2026With two positive Phase 3 trials in breast cancer, these data reinforce the potential of iza-bren to further redefine…
247wallst.com Bristol-Myers Squibb Company Looking ahead to 2030, our model projects BMY could trade at an average price of $96.86, with a potential range between $72.64 and $121.07. This represents a potential 64.7% return from today’s price.
ainvest.com Halozyme: The Cliff Is 2032, Not 2027 Halozyme (HALO) shares fell 30% after Merck won all 14 U.S. patent reviews and German courts lifted injunctions on Keytruda, ...
ainvest.com Pfizer's 6.3% Dividend Leans on a Drug That Loses Its Patent in 2028 Pfizer's 6.27% dividend yield relies on Eliquis, a drug losing U.S. patent protection in 2028, which currently drives 20% of ...
ad-hoc-news.de Bristol Myers Squibb stock: New cancer trial with Erasca Bristol Myers Squibb and Erasca agreed on November 17, 2026, to evaluate Erasca's ERAS-0015 with BMS's investigational PRMT5 inhibitor navlimetostat in a Phase 1/2 study targeting MTAP-deleted ...
theglobeandmail.com Bristol-Myers Squibb (BMY) Gets a Hold from Leerink Partners Detailed price information for Bristol-Myers Squibb (BMY-N) from The Globe and Mail including charting and trades.
msn.com Porównaliśmy ceny pajdy ze smalcem na jarmarkach. Tu jest zdecydowanie najtaniej Pajda ze smalcem najtaniej kosztuje w Gdańsku – za podstawową porcję zapłacimy tam 12 zł. Na jarmarkach bożonarodzeniowych w ...
